<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of malignant germ cell tumors of the ovary
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of malignant germ cell tumors of the ovary
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of malignant germ cell tumors of the ovary
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Gershenson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara Goff, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alberto S Pappo, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Don S Dizon, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 13, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ovarian germ cell tumors (OGCTs) are derived from primordial germ cells of the ovary  (
         <a class="graphic graphic_figure graphicRef72286" href="/z/d/graphic/72286.html" rel="external">
          figure 1
         </a>
         ). They may be benign or malignant. Malignant germ cell cancers of the ovary include dysgerminomas and nondysgerminomas, which include immature teratomas, embryonal cell carcinoma, yolk sac tumors, primary ovarian (nongestational) choriocarcinomas, polyembryoma, and mixed germ cell tumors [
         <a href="#rid1">
          1
         </a>
         ]. In contrast to epithelial ovarian cancer, they constitute a rare form of ovarian malignancy. (See
         <a class="medical medical_review" href="/z/d/html/83397.html" rel="external">
          "Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum"
         </a>
         .)
        </p>
        <p>
         Dysgerminomas differ from other malignant OGCTs in several ways: they are more likely to be localized to the ovary at diagnosis (approximately two-thirds of cases are stage IA  (
         <a class="graphic graphic_table graphicRef113545" href="/z/d/graphic/113545.html" rel="external">
          table 1
         </a>
         )), bilateral ovarian involvement is more common (10 to 15 percent), they are more likely to spread in a predictable fashion, and they are more sensitive to radiation therapy.
        </p>
        <p>
         The management of malignant OGCTs will be reviewed here. Pathology and clinical manifestations of these neoplasms, as well as the treatment of benign OGCTs, are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/3236.html" rel="external">
          "Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1965172">
         <span class="h1">
          OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, the treatment principles for all types of malignant OGCTs are similar to those that guide the management of the more common epithelial ovarian cancer (EOC), with some exceptions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Many OGCTs produce tumor products (alpha fetoprotein [AFP], human chorionic gonadotropin [hCG], lactate dehydrogenase [LDH]) that can be measured in the serum. The presence of these markers provides a highly sensitive and specific indicator of the presence of certain histologic components  (
         <a class="graphic graphic_table graphicRef55817" href="/z/d/graphic/55817.html" rel="external">
          table 2
         </a>
         ). Testing for serum tumor markers prior to definitive treatment can provide a diagnostic clue to the presence of an OGCT. In a child, teen, or young woman, the tumor marker results may help with surgical planning, resulting in the preservation of fertility potential. Furthermore, serial assay of these tumor markers is useful for monitoring the response to chemotherapy and for subsequent post-treatment follow-up. (See
         <a class="medical medical_review" href="/z/d/html/3238.html" rel="external">
          "Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surgery is required for diagnosis, staging, and treatment. As with EOC, adults with OGCTs should undergo a thorough exploration of the abdomen with complete surgical staging (for apparent early-stage disease) and optimal cytoreduction (for metastatic disease) when safe and feasible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most OGCTs are stage I  (
         <a class="graphic graphic_table graphicRef113545" href="/z/d/graphic/113545.html" rel="external">
          table 1
         </a>
         ) at initial presentation, and most patients can be safely treated with fertility-preserving surgery rather than total abdominal hysterectomy and bilateral salpingo-oophorectomy. (See
         <a class="local">
          'Fertility-sparing surgery'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant OGCTs occurring in adult women are highly sensitive to platinum-based chemotherapy, and treatment can be curative. This fact, coupled with the poor outcomes from surgery alone (even for stage I disease), has led to routine administration of adjuvant cisplatin-based chemotherapy to most adult patients except those with stage IA or IB dysgerminoma and stage IA, grade 1 immature teratoma.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          SURGICAL STAGING AND PRIMARY CYTOREDUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical management of OGCTs is both diagnostic and therapeutic. In general, the scope of the operative procedure depends upon the surgical findings and the patient's desire to maintain fertility and/or avoid exogenous estrogen supplementation.
        </p>
        <p>
         Areas of controversy include: whether hysterectomy and bilateral salpingo-oophorectomy are required for optimal outcomes in patients with apparent early-stage disease, the extent of cytoreductive surgery in patients with advanced-stage disease, and the role of minimally invasive surgery. (See
         <a class="medical medical_review" href="/z/d/html/3193.html" rel="external">
          "Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Surgical staging", section on 'Open laparotomy versus minimally invasive surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1965526">
         <span class="h2">
          Staging system
         </span>
         <span class="headingEndMark">
          —
         </span>
         The staging system used for OGCTs is identical to that used for epithelial ovarian cancer (EOC)  (
         <a class="graphic graphic_table graphicRef113545" href="/z/d/graphic/113545.html" rel="external">
          table 1
         </a>
         ). Malignant OGCTs spread via the lymphatics, bloodstream, or by peritoneal surface dissemination.
        </p>
        <p class="headingAnchor" id="H1965593">
         <span class="h2">
          Staging procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         The staging procedure for adult women with OGCTs is the same as for EOC. This is described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3193.html" rel="external">
          "Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Surgical staging"
         </a>
         .)
        </p>
        <p>
         The standard staging procedure for ovarian cancer is total extrafascial hysterectomy with bilateral salpingo-oophorectomy and pelvic and para-aortic lymph node dissection. However, OGCTs often affect children, adolescents, or young women, and fertility-sparing surgery should be performed when possible. (See
         <a class="local">
          'Children and adolescents'
         </a>
         below and
         <a class="local">
          'Fertility-sparing surgery'
         </a>
         below.)
        </p>
        <p>
         Peritoneal cytology is collected after the incision is made. Staging also includes omentectomy and cytology of the diaphragm. As with other intra-abdominal gynecologic malignancies, complete staging includes biopsy of any areas where metastases are suspected. Cytoreduction often is performed when metastases are evident.
        </p>
        <p>
         Laparotomy is generally used. Laparoscopic or robot-assisted approaches are not considered prudent by some experts, but some surgeons have reported success with these techniques [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1965576">
         <span class="h3">
          Lymphadenectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall prevalence of lymph node involvement varies by histology [
         <a href="#rid3">
          3,4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysgerminoma (18 to 28 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mixed germ cell tumors (7 to 16 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant teratoma (3 to 8 percent)
        </p>
        <p>
        </p>
        <p>
         Lymphadenectomy is generally performed as part of the surgical procedure to guide postoperative treatment recommendations; however, it is associated with some morbidity (eg, increased intraoperative injury, lymphedema). (See
         <a class="local">
          'Adjuvant treatment'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3182.html" rel="external">
          "Pelvic and paraaortic lymphadenectomy in gynecologic cancers", section on 'Complications'
         </a>
         .)
        </p>
        <p>
         In one large retrospective study, while there was no difference in survival among patients who did or did not undergo lymphadenectomy, lymph node involvement was an independent predictor of poor survival (hazard ratio 2.4, 95% CI 1.0-5.53) [
         <a href="#rid4">
          4
         </a>
         ]. This is consistent with other observational data [
         <a href="#rid3">
          3
         </a>
         ]. In a study of 2774 patients from the National Cancer Database with apparent stage I disease, those undergoing lymphadenectomy (51.4 percent) compared with those not undergoing lymphadenectomy had similar overall survival [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3193.html" rel="external">
          "Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Surgical staging", section on 'Lymph node evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Initial cytoreduction for advanced disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with advanced tumors, optimal cytoreductive surgery is associated with improved outcomes, particularly for nondysgerminomatous tumors. However, the benefits and risks of aggressive cytoreductive maneuvers for metastatic disease must be carefully weighed for these chemotherapy-sensitive tumors.
        </p>
        <p>
         If advanced disease is encountered at initial exploration, cytoreductive surgery should be attempted, following the same principles as established for advanced EOC. As much tumor should be resected as is technically feasible and safe. (See
         <a class="medical medical_review" href="/z/d/html/122088.html" rel="external">
          "Cancer of the ovary, fallopian tube, and peritoneum: Surgical cytoreduction"
         </a>
         .)
        </p>
        <p>
         Due to the rarity of malignant OGCTs, the benefit of cytoreductive surgery is less well-established than with EOC. However, surgical debulking of large tumor masses plays a central role in the upfront treatment of OGCTs. Despite the sensitivity of OGCTs to platinum-based chemotherapy, tumor volume is one of the most important prognostic factors for outcome. In most clinical series, prognosis is worse for women with metastatic or incompletely resected disease  (
         <a class="graphic graphic_table graphicRef79165" href="/z/d/graphic/79165.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
         Although randomized trials have not been conducted, there is observational evidence that patients with malignant OGCTs who have optimally debulked disease (ie, all areas of residual disease less than 2 cm) have a higher complete remission rate from chemotherapy and better long-term outcomes than those with bulky unresectable disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an early trial from the Gynecologic Oncology Group (GOG), the likelihood of disease progression after postoperative chemotherapy with
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9318" href="/z/d/drug information/9318.html" rel="external">
          dactinomycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (VAC) was significantly higher in patients who had incompletely as compared with completely resected disease at the time of primary surgery (68 versus 28 percent, respectively) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent GOG trial examined the benefit of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">
          vinblastine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         (PVB) chemotherapy followed by restaging laparotomy in 111 women with advanced (stage II to IV  (
         <a class="graphic graphic_table graphicRef113545" href="/z/d/graphic/113545.html" rel="external">
          table 1
         </a>
         )) or recurrent malignant OGCTs [
         <a href="#rid6">
          6
         </a>
         ]. Eighty-nine had initial cytoreductive surgery, which was recommended but not mandated. Patients who had tumors other than dysgerminoma and clinically non-measurable disease after initial surgery had a significantly greater chance of remaining progression free than those with measurable disease (65 versus 34 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optimal debulking may be more critical for nondysgerminoma tumors. This was shown in a case series of 33 patients with malignant OGCTs, 13 of whom had bulky (&gt;10 cm) residual tumor after primary surgery [
         <a href="#rid7">
          7
         </a>
         ]. All 11 patients with dysgerminoma achieved a complete sustained remission after
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (BEP), regardless of the size of the postsurgery residual disease. Four of six patients with bulky nondysgerminomatous OGCTs were complete responders to chemotherapy; three sustained long-term. By contrast, 15 of 16 nonbulky nondysgerminomatous OGCTs achieved a complete response to chemotherapy, which was durable in 14 cases.
        </p>
        <p>
        </p>
        <p>
         As a result, the majority of women with OGCTs undergo maximal surgical cytoreduction before starting chemotherapy. The central role that upfront surgery plays in OGCTs is in direct contrast to testicular cancer, where surgery is typically reserved for residual masses that remain after chemotherapy. (See
         <a class="medical medical_review" href="/z/d/html/2952.html" rel="external">
          "Approach to surgery following chemotherapy for advanced testicular germ cell tumors"
         </a>
         .)
        </p>
        <p>
         Despite the importance of upfront surgical debulking, the surgeon should keep in mind the sensitivity of these tumors to cisplatin-based chemotherapy when aggressive resection of metastatic disease is considered, particularly in patients with dysgerminomas. With modern cisplatin-based adjuvant chemotherapy, approximately 80 percent of patients who present with advanced disease will be long-term survivors, even if they have residual disease remaining after cytoreductive surgery [
         <a href="#rid8">
          8-12
         </a>
         ]. (See
         <a class="local">
          'Adjuvant treatment'
         </a>
         below.)
        </p>
        <p>
         In rare instances, the extent of metastatic disease or effusions may be so great or comorbidities may be so significant that a primary surgical approach is not warranted. In such cases, neoadjuvant chemotherapy should be administered. However, little information on outcomes exists, and clinical trials are needed to evaluate outcomes [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H466456963">
         <span class="h1">
          ADJUVANT TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We advise most women to undergo adjuvant chemotherapy after surgery for OGCTs. Exceptions to this include adult patients with stage IA, grade 1 immature teratoma and stage IA and IB dysgerminoma because their outcomes are excellent following surgery alone. Although 15 to 25 percent of such patients will recur, virtually all of these women can be treated with platinum-based chemotherapy or radiation therapy (RT) with curative intent  (
         <a class="graphic graphic_table graphicRef78392" href="/z/d/graphic/78392.html" rel="external">
          table 4
         </a>
         ). Long-term cure rates are &gt;90 percent. The approach to women with de novo stage IV OGCT, as well as the approach to children with OGCTs, is discussed below. (See
         <a class="local">
          'Treatment of de novo stage IV disease'
         </a>
         below and
         <a class="local">
          'Children and adolescents'
         </a>
         below.)
        </p>
        <p>
         Due to the rarity of these tumors, data on efficacy are limited to single-arm clinical trials [
         <a href="#rid6">
          6,15
         </a>
         ] or retrospective series [
         <a href="#rid9">
          9,12,16-21
         </a>
         ], often with small numbers of patients enrolled or evaluated. However, as with testicular germ cell tumors (GCTs), the receipt of adjuvant chemotherapy appears to have improved overall survival following surgery when compared with historical controls. These gains in outcome date back to one of the original studies from 1975, which reported that combination chemotherapy (
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         , actinomycin-D, plus
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) resulted in the survival of 15 of 20 women with nondysgerminomas [
         <a href="#rid22">
          22
         </a>
         ]. The evolution of chemotherapy to incorporate platinum agents mirrors that of testicular GCTs, and cisplatin-based chemotherapy is now considered the standard of care for patients in whom adjuvant treatment is indicated. Applying the same cisplatin-based combination chemotherapy regimens to OGCTs has resulted in dramatically improved outcomes; at least 90 percent of women with early-stage OGCTs and up to 80 percent of those with advanced disease are long-term survivors [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1056139004">
         <span class="h2">
          Platinum-based therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple platinum-based regimens have been used for OGCTs, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          Bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (BEP)  (
         <a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">
          table 5
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          Etoposide
         </a>
         and
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         (see
         <a class="local">
          'Substitution of cisplatin with carboplatin'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          Etoposide
         </a>
         and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (EP). While this regimen has very limited use given preference for BEP, it is an appropriate option for patients who cannot tolerate
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         . Based on data from the treatment of testicular GCTs, EP and BEP are likely to have equivalent activity. Although there are no prospective data to inform the optimal number of cycles, three cycles of EP are usually administered for patients deemed to be at a lower risk of recurrence (eg, a "good-risk" cohort). For those with a higher risk of relapse, four cycles are administered.
        </p>
        <p>
        </p>
        <p>
         Unfortunately, there is no consensus definition for prognostic risk groups. One simple categorization would take into account stage at diagnosis (see
         <a class="local">
          'Prognosis'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Good risk – Stage IA disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermediate risk – Stage IC to III
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor risk – Stage IV
        </p>
        <p>
        </p>
        <p>
         Although there are only limited data,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         may be a reasonable alternative for women who cannot tolerate
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         for whatever reason.
        </p>
        <p class="headingAnchor" id="H1056139481">
         <span class="h3">
          Bleomycin, etoposide, and cisplatin
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients, the regimen of choice is BEP. Long-term survival rates with surgery followed by adjuvant BEP are 95 to 100 percent for early-stage nondysgerminomatous tumors and 75 to 80 percent for those with advanced disease at presentation [
         <a href="#rid23">
          23,24
         </a>
         ]. Results are even more favorable for ovarian dysgerminomas regardless of stage at presentation [
         <a href="#rid9">
          9,25
         </a>
         ]. However, the toxicities associated with this regimen can be significant, including risks for acute- and later-onset pulmonary toxicity associated with
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         , an increased risk of therapy-related myeloid neoplasms due to
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , and risks for long-term renal and neurotoxicity due to
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">
          "Bleomycin-induced lung injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4506.html" rel="external">
          "Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7231.html" rel="external">
          "Cisplatin nephrotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">
          "Overview of neurologic complications of platinum-based chemotherapy"
         </a>
         .)
        </p>
        <p>
         For patients who cannot receive
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         for whatever reason, alternative regimens incorporate EP, based on an extrapolation from data in men with testicular GCTs, or
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         . (See
         <a class="local">
          'Substitution of cisplatin with carboplatin'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1056138862">
         <span class="h4">
          Dose and schedule
         </span>
         <span class="headingEndMark">
          —
         </span>
         As in the treatment of testicular GCTs, full doses of all agents should be administered at the scheduled time regardless of the white blood cell count; the curative potential of systemic chemotherapy may otherwise be compromised. Low blood cell counts at the beginning of a scheduled subsequent course of chemotherapy do not mandate dose reductions or treatment delay. If the previous cycle was complicated by febrile neutropenia or some other significant clinical event, the administration of hematopoietic growth factors during subsequent cycles is warranted in order to avoid dose reduction. (See
         <a class="medical medical_review" href="/z/d/html/16889.html" rel="external">
          "Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation", section on 'Secondary prophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H466457791">
         <span class="h5">
          Nondysgerminomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the data are limited, adjuvant BEP  (
         <a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">
          table 5
         </a>
         ) for three cycles appears to prevent recurrences, especially in well-staged patients. This was shown in a single-arm study conducted by the Gynecologic Oncology Group (GOG) where 93 women with stage I, II, or III nondysgerminomatous OGCTs were treated with three courses of BEP [
         <a href="#rid15">
          15
         </a>
         ]. With a range of follow-up between 4 and 90 months, 91 were alive and free of recurrence. However, two patients developed a treatment-related hematologic secondary malignancy. (See
         <a class="local">
          'Secondary malignancies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H466457797">
         <span class="h5">
          Dysgerminomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         As in the treatment of nondysgerminoma, the regimen of choice is BEP. The optimal number of cycles has not been established in randomized trials. In our practice, we administer three courses of adjuvant therapy for completely resected stage I disease and four courses for those with more advanced-stage disease. In one representative series of 26 patients with pure ovarian dysgerminoma (54 percent stage IIIC or IV  (
         <a class="graphic graphic_table graphicRef113545" href="/z/d/graphic/113545.html" rel="external">
          table 1
         </a>
         )), 25 (96 percent) remained continuously disease-free following at least three cycles of BEP chemotherapy [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H466458148">
         <span class="h2">
          Substitution of cisplatin with carboplatin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The available data, much of them obtained in children with GCTs or in women with completely resected dysgerminoma, suggest that in contrast to testicular GCTs,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         may represent an acceptable therapeutic alternative to
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         for the treatment of OGCTs [
         <a href="#rid9">
          9,10
         </a>
         ]. In a review of 126 patients with advanced-stage dysgerminoma from six clinical trials (three pediatric and three adult), those receiving carboplatin-based (56 patients) compared with cisplatin-based (70 patients) chemotherapy had similar five-year event-free survival [
         <a href="#rid27">
          27
         </a>
         ]. Although further study is needed, there is a clear trend toward the use of carboplatin-based regimens for metastatic dysgerminoma. The administration of carboplatin in younger patients is discussed below. (See
         <a class="local">
          'Children and adolescents'
         </a>
         below.)
        </p>
        <p>
         In a study performed by the GOG,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         plus
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         was administered to 42 patients with completely resected stage IB to III dysgerminoma [
         <a href="#rid28">
          28
         </a>
         ]. Treatment consisted of three 28-day courses of carboplatin (400 mg/m
         <sup>
          2
         </sup>
         on day 1) plus etoposide (120 mg/m
         <sup>
          2
         </sup>
         on days 1, 2, and 3). With a median follow-up of 7.8 years, no patient had a disease recurrence, although one died of a presumably unrelated lung adenocarcinoma.
        </p>
        <p class="headingAnchor" id="H2082010519">
         <span class="h2">
          Surveillance as an alternative option
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although surveillance following primary surgery cannot be routinely recommended for adult patients with a malignant OGCT, there are some data that surveillance might be appropriate, especially for those patients with particular subtypes of stage IA nondysgerminoma (eg, yolk sac tumor, immature teratoma, mixed GCT, embryonal carcinoma) [
         <a href="#rid29">
          29-32
         </a>
         ]. In one study, the outcomes of 31 patients with stage I disease (median age, 22; range 6 to 45 years) who underwent surgery followed by surveillance were reviewed [
         <a href="#rid29">
          29
         </a>
         ]. With a median follow-up of 11.4 years, the relapse rate was 23 percent (7 of 31 patients). Of these seven patients, six went into remission with chemotherapy. AGCT 1531 is an ongoing international trial sponsored by the Children's Oncology Group and in collaboration with the adult Clinical Trials Network in the United States [
         <a href="#rid33">
          33
         </a>
         ]. In this trial, the low-risk cohort consisting of patients up to 50 years of age with stage I non-dysgerminoma or stage I, grade 2 or 3 immature teratoma are followed with active surveillance following primary surgery. In the standard-risk cohort, which includes children as well as adults up to age 25 years with International Federation of Gynecology and Obstetrics (FIGO) stage IC to III OGCTs, patients are randomly assigned to either cisplatin-based or carboplatin-based chemotherapy.
        </p>
        <p class="headingAnchor" id="H1056139251">
         <span class="h2">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We reserve RT for patients with a dysgerminoma who are not candidates for chemotherapy for whatever reason [
         <a href="#rid34">
          34
         </a>
         ]. RT is not effective for nondysgerminomas, which tend to be radioresistant [
         <a href="#rid35">
          35,36
         </a>
         ]. Although adjuvant RT is effective in the treatment of dysgerminomas [
         <a href="#rid34">
          34,37-40
         </a>
         ], it is not utilized due to the availability of chemotherapy because chemotherapy results in less long-term toxicity.
        </p>
        <p class="headingAnchor" id="H466460365">
         <span class="h1">
          TREATMENT OF DE NOVO STAGE IV DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who present with de novo stage IV disease should be offered an attempt at maximal cytoreduction, including resection of metastatic disease if applicable. Following surgery, at least four courses of
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (BEP)  (
         <a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">
          table 5
         </a>
         ) should be given [
         <a href="#rid41">
          41
         </a>
         ]. Of note, even for women with incompletely resected disease, long-term survival can be expected in over half of these patients [
         <a href="#rid23">
          23,42,43
         </a>
         ]. For patients who are not surgical candidates at the time of presentation, we offer neoadjuvant chemotherapy followed by interval debulking surgery [
         <a href="#rid13">
          13,14
         </a>
         ]. There are ongoing trials, principally for patients with high-risk testicular cancer, exploring the effectiveness of more aggressive therapies, including accelerated BEP or a combination of
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         and BEP.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          FERTILITY PRESERVATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because most women with OGCTs are young and wish to preserve future childbearing potential, fertility-sparing options should be explored.
        </p>
        <p class="headingAnchor" id="H467455">
         <span class="h2">
          Fertility-sparing surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unilateral salpingo-oophorectomy with preservation of a normal-appearing uterus and contralateral ovary is an option for women with clinically apparent early-stage disease. Even after chemotherapy, at least 80 percent of these women will resume normal menstrual function, and those who become pregnant appear to have no increase in pregnancy complications [
         <a href="#rid44">
          44,45
         </a>
         ]. (See
         <a class="local">
          'Premature ovarian insufficiency'
         </a>
         below and
         <a class="local">
          'Pregnant women'
         </a>
         below.)
        </p>
        <p>
         The ipsilateral fallopian tube is removed because of the rich lymphovascular connections between the tube and ovary. Oncologic outcomes are not compromised by conservative surgery, even in the face of bulky metastatic disease elsewhere [
         <a href="#rid42">
          42,46-51
         </a>
         ].
        </p>
        <p>
         The risk of occult contralateral ovarian involvement appears to be greatest with dysgerminomas, although it is likely no higher than 5 to 10 percent [
         <a href="#rid52">
          52
         </a>
         ]. For example, in one study of 98 patients with stage IA dysgerminoma, nine developed disease in the contralateral ovary [
         <a href="#rid52">
          52
         </a>
         ]. These were presumably occult primaries undetected at the time of initial surgery. While some surgeons routinely perform a wedge biopsy of a normal-appearing contralateral ovary, this practice is not universally accepted, as these tumors are particularly sensitive to chemotherapy, and salvage rates are high. (See
         <a class="medical medical_review" href="/z/d/html/3236.html" rel="external">
          "Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis", section on 'Dysgerminoma'
         </a>
         .)
        </p>
        <p>
         Unnecessary surgery on normal ovaries, even a biopsy, should be avoided because postoperative adhesions are common and can impair fertility. If bilateral salpingo-oophorectomy is required, women with a uterus but no ovaries can become pregnant using an egg donor or their own cryopreserved fertilized eggs/ovarian tissue/oocytes. In addition, women with an ovary but no uterus should be counseled about the potential for use of a gestational carrier. (See
         <a class="medical medical_review" href="/z/d/html/5448.html" rel="external">
          "Female infertility: Treatments"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">
          "Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H467428">
         <span class="h2">
          Oocyte cryopreservation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most established method for preservation of child-bearing potential in women at risk of gonadal failure is embryo cryopreservation. For women who do not have a participating male partner and are not interested in using donor sperm, oocyte cryopreservation is also an option. The decision concerning use of assisted reproductive techniques prior to initiation of chemotherapy should be individualized and must be balanced against the delay in starting therapy. This topic is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">
          "Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H467320">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies have addressed prognostic factors that might permit risk stratification for future treatment assignment in OGCTs [
         <a href="#rid23">
          23,53-55
         </a>
         ]. As an example, the importance of stage and tumor markers was addressed in an analysis of 148 women with malignant OGCTs, 113 of whom received platinum-based chemotherapy [
         <a href="#rid23">
          23
         </a>
         ]. Five-year survival rates were:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage IC disease (or stage I disease with persistent/increasing tumor markers) – 100 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage II – 85 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage III – 79 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage IV – 71 percent
        </p>
        <p>
        </p>
        <p>
         In addition, tumor markers appear to have prognostic significance in this disease. In the study discussed above, patients who had elevations of both beta-human chorionic gonadotropin (beta-hCG) and alpha-fetoprotein (AFP) were almost five times more likely to die of their disease compared with those with initially normal levels of both markers (one-year survival 50 versus 90 percent, respectively) [
         <a href="#rid23">
          23
         </a>
         ]. An unanswered clinical question is whether the poor prognosis associated with these factors can be reversed by altering the initial treatment strategy [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          POST-TREATMENT SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most recurrences develop within two years of initial therapy, although as with testicular seminomas, dysgerminomas may recur later (after five years or more).
        </p>
        <p>
         The optimal post-treatment surveillance strategy has not been established. A reasonable strategy includes the following [
         <a href="#rid41">
          41,56
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor markers (alpha fetoprotein [AFP], human chorionic gonadotropin [hCG]) repeated regularly. In our practice, we repeat them every month for a period of two years and then less frequently over time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Review of symptoms and physical examination every two to four months for the first two years, followed by annual visits every year.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiographic imaging every two to four months for the first two years only in patients whose initial tumor marker levels are not elevated.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8425894">
         <span class="h1">
          POST-TREATMENT ISSUES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The issues for women with OGCTs after treatment has completed are similar to those for women treated for epithelial ovarian cancer (EOC). However, given that these tumors tend to occur in younger women, specific concerns may be present, which are addressed below. Further discussion of survivorship issues after treatment for EOC is covered separately. (See
         <a class="medical medical_review" href="/z/d/html/17007.html" rel="external">
          "Approach to survivors of epithelial ovarian, fallopian tube, or peritoneal carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8425901">
         <span class="h2">
          Premature ovarian insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although ovarian dysfunction or premature ovarian insufficiency is a risk of chemotherapy, most women who receive platinum-based therapy for three to four cycles recover normal ovarian function [
         <a href="#rid6">
          6,11,12,26,44-48
         </a>
         ]. For these patients, fertility is often spared. However, premature ovarian insufficiency has been reported in women who previously received chemotherapy as children, adolescents, or young adults [
         <a href="#rid57">
          57,58
         </a>
         ]. As an example, one study reported that the incidence of nonsurgical premature ovarian insufficiency was higher among survivors of childhood cancer than control siblings (8 versus 0.8 percent). These data emphasize the importance of pretreatment counseling and planning to ensure the most appropriate treatment is rendered, taking into account the age of the patient and her desires regarding future fertility. (See
         <a class="medical medical_review" href="/z/d/html/4801.html" rel="external">
          "Overview of infertility and pregnancy outcome in cancer survivors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">
          "Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"
         </a>
         .)
        </p>
        <p>
         The impact of platinum-based chemotherapy on adult women’s gonadal function was demonstrated in a representative series of 71 patients treated with fertility-sparing surgery and combination chemotherapy (including
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ). Of these, 62 (87 percent) resumed normal menstruation, and 24 of these women subsequently had 37 offspring [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         In a review of 47 studies that included 2189 patients who underwent fertility-sparing surgery for malignant OGCTs, 79.9 percent received chemotherapy [
         <a href="#rid59">
          59
         </a>
         ]. Overall, the rate of premature ovarian failure was 3.7 percent, and the fecundity rate was 24.6 percent. Of patients attempting pregnancy, 80.6 percent had at least one pregnancy.
        </p>
        <p>
         Postmenopausal hormone therapy in ovarian cancer survivors is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/17007.html" rel="external">
          "Approach to survivors of epithelial ovarian, fallopian tube, or peritoneal carcinoma", section on 'Menopause'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8425994">
         <span class="h2">
          Secondary malignancies
         </span>
         <span class="headingEndMark">
          —
         </span>
         An important cause of late morbidity and mortality in patients undergoing treatment for germ cell tumors (GCTs) is the development of secondary malignancies, both solid tumors and leukemia.
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          Etoposide
         </a>
         in particular has been implicated in the development of treatment-related leukemias. The risk is dose-related. The incidence of leukemia is &lt;0.5 percent in patients receiving a typical three- or four-cycle course of
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         , etoposide, and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (BEP; cumulative etoposide dose &lt;2000 mg/m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid60">
          60
         </a>
         ] compared with as high as 5 percent (representing a 336-fold increase in the likelihood of leukemia) in those receiving over 2000 mg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
         Despite the risk of secondary leukemia, risk-benefit analyses have concluded that etoposide-containing chemotherapy regimens are beneficial in advanced GCTs; one case of treatment-induced leukemia would be expected for every 20 additionally cured patients who receive BEP as compared with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">
          vinblastine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         (PVB). The risk-benefit balance for low-risk disease, or for high-dose
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         in the salvage setting, is less clear. This topic is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">
          "Treatment-related toxicity in testicular germ cell tumors", section on 'Second malignancies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8426015">
         <span class="h2">
          Other issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         The limited data on OGCT survivors suggest they are at risk for health disparities and chronic toxicities. For example, one study performed in the United States compared these issues among survivors who were approximately 10 years out from diagnosis (n = 132) and age-matched controls (n = 137) [
         <a href="#rid62">
          62
         </a>
         ]. Of those treated for OGCT, 87 percent had received
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         . Major findings were that survivors were:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significantly more likely to be diagnosed with hypertension compared with age-matched controls (17 versus 8 percent, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More likely to have hypercholesterolemia (10 versus 4 percent), though this difference was not statistically significant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More likely to report hearing loss (5 versus 2 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significantly more likely to report denial for health insurance (16 versus 4 percent), though overall, health care utilization was similar.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H36">
         <span class="h1">
          RELAPSED DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of recurrences develop in the first two years after completion of therapy. As in men with a history of testicular cancer, recurrence is usually detected by a rise in serum tumor markers or the evolution of new disease on radiographic studies. Given the rarity of these tumors, the data to inform the management of patients are of very limited quality [
         <a href="#rid63">
          63
         </a>
         ]. Even small single-arm trials that were open to both male and female patients who had relapsed disease enrolled very few women [
         <a href="#rid64">
          64,65
         </a>
         ]. Therefore, the approach to these patients is based on an extrapolation of the management of men with relapsed germ cell tumors. (See
         <a class="medical medical_review" href="/z/d/html/2999.html" rel="external">
          "Diagnosis and treatment of relapsed and refractory testicular germ cell tumors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who were originally treated with surgery alone and then developed relapsed disease should meet with a gynecologic oncologist for consideration of secondary surgery. Regardless of whether surgery is performed, standard first-line chemotherapy should be administered. As in the adjuvant setting, the regimen of choice is
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (BEP). (See
         <a class="local">
          'Adjuvant treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who were previously treated with chemotherapy (as adjuvant therapy or first-line treatment of stage IV disease) and did not exhibit refractory disease (ie, no evidence of disease progression during or immediately after prior treatment), repeat treatment with a platinum-based regimen is indicated [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who relapse despite first-line treatment for recurrent disease and those with refractory disease, we utilize the approach to men with relapsed and refractory testicular cancer.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1966290">
         <span class="h2">
          Role of surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main utility of surgery for women with recurrent OGCTs is the ability to resect limited metastatic disease, which might alter the subsequent medical treatment. Although only low-quality data are available, they suggest that surgical resection may afford a survival advantage in properly selected patients [
         <a href="#rid66">
          66-68
         </a>
         ]. For example, one single-institution study included 34 women, all of whom progressed after initial chemotherapy and were treated with second-line chemotherapy followed by surgical resection [
         <a href="#rid68">
          68
         </a>
         ]. Compared with women who had residual disease &gt;1 cm, the five-year survival rate was higher among those who were rendered macroscopically disease-free or who had residual tumor ≤1 cm (61 versus 14 percent, respectively). These data suggest that women with recurrent disease may benefit from surgical resection, especially if the disease appears to be resectable.
        </p>
        <p class="headingAnchor" id="H466456853">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H466456752">
         <span class="h2">
          Children and adolescents
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment approach to girls with a germ cell tumor (GCT) differs from that for adult women. However, the optimal approach has not yet been characterized, primarily due to the rarity of these cancers. We agree with the position of the Children’s Oncology Group Rare Tumors Disease Committee that further evidence is needed, which will only come through international collaborations in clinical research [
         <a href="#rid69">
          69
         </a>
         ]. An example of how pediatric care differs from management of these tumors in adults is that necessity for and extent of comprehensive surgical staging are controversial in children and adolescents, though not in adult women in whom staging is indicated. (See
         <a class="local">
          'Surgical staging and primary cytoreduction'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H544590387">
         <span class="h3">
          Primary treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The contemporary pediatric surgical approach tends to consist of peritoneal cytology, primary tumor removal, and biopsy or excision of suspicious implants or lymph nodes, with no further biopsies. Complete surgical staging, which is the standard approach for adult women, is generally not performed in pediatric patients. (See
         <a class="local">
          'Surgical staging and primary cytoreduction'
         </a>
         above.)
        </p>
        <p>
         Future investigations are needed to resolve this disparity in the surgical approach to pediatric and adult patients. This disparity is illustrated in a combined retrospective study performed by the Pediatric Oncology Group and Children’s Cancer Study Group that included 131 girls (mean age, 11.9 years), all of whom underwent surgical resection (if possible for those who presented with advanced-stage disease) followed by adjuvant platinum-based chemotherapy [
         <a href="#rid50">
          50
         </a>
         ]. The main findings were:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Despite stage at presentation, complete surgical staging was seldom performed. Among the surgical omissions were no nodal sampling (97 percent), no omentectomy (36 percent), and no peritoneal cytology (21 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The six-year overall survival rates were 95, 94, 97, and 93 percent for stages I (n = 41), II (n = 16), III (n = 58), and IV (n = 16), respectively. The six-year event-free survival rates by stage were 95, 88, 97, and 87 percent.
        </p>
        <p>
        </p>
        <p>
         Although this was a retrospective study, pediatric and adolescent patients appear to have an excellent outcome, likely due to the administration of adjuvant chemotherapy in all patients. However, whether chemotherapy is necessary for all patients is not answered by this study and points to the potential importance of comprehensive surgical staging as a way to help stratify patients at a higher risk of recurrence, for whom adjuvant therapy should be administered.
        </p>
        <p>
         A study of the Surveillance, Epidemiology, and End Results database identified 2238 patients who underwent surgery for malignant OGCTs [
         <a href="#rid70">
          70
         </a>
         ]. Over time, there was a decrease in the rate of omentectomy in both the pediatric and young adult groups, and a decrease in the rate of hysterectomy in the young adult group only, suggesting a trend toward less extensive surgery in young women.
        </p>
        <p class="headingAnchor" id="H544590393">
         <span class="h3">
          Treatment after surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although limited data are available, surveillance for girls with stage IA malignant OGCTs appears to be reasonable. In one study, 25 girls with International Federation of Gynecology and Obstetrics (FIGO) stage IA malignant OGCTs were enrolled in a study of the Children’s Oncology Group and underwent surveillance [
         <a href="#rid31">
          31
         </a>
         ]. Although 12 patients had persistent disease or experienced recurrence, 11 were successfully treated with chemotherapy at the time of relapse. An international clinical trial for girls and women with stage IA and IB malignant OGCTs, excluding grade 1 immature teratoma and pure dysgerminoma, is actively recruiting.
        </p>
        <p>
         Adjuvant chemotherapy is routinely offered to patients with higher-stage disease. The exception is for patients with metastatic immature teratoma, in whom postoperative chemotherapy has not been shown to decrease relapses, based on a combined data analysis of seven pediatric trials including 98 patients, of whom 90 were treated with surgery alone [
         <a href="#rid71">
          71
         </a>
         ]. In general, we advocate for the use of
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (BEP) if chemotherapy is indicated. However, limited data suggest that
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         can be used instead of cisplatin in an attempt to reduce toxicities while preserving efficacy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one report, 137 children with extracranial GCTs (recurrent stage I disease and all other patients) received
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         (600 mg/m
         <sup>
          2
         </sup>
         on day 2),
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         (120 mg/m
         <sup>
          2
         </sup>
         on days 1 through 3), and
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         (15 mg/m
         <sup>
          2
         </sup>
         on day 3) (JEB) every three to four weeks for two courses beyond clinical remission [
         <a href="#rid10">
          10
         </a>
         ]. The five-year and event-free survival rates were 91 and 88 percent, respectively. No patient had significant renal toxicity, and only one had severe deafness (as a result of a middle ear hemorrhage).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Favorable long-term outcomes with a similar regimen (
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         600 mg/m
         <sup>
          2
         </sup>
         on day 2,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         150 mg/m
         <sup>
          2
         </sup>
         on days 1 through 3, and
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         10 mg/m
         <sup>
          2
         </sup>
         on day 3) were also noted in a series of 23 consecutive children with advanced GCTs (15 females, six primary to the ovary, 19 stage III or IV) [
         <a href="#rid72">
          72
         </a>
         ]. With a median 58-month follow-up, event-free and overall survival rates were 87 and 91 percent, respectively.
        </p>
        <p>
        </p>
        <p>
         Although some data support the use of
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         rather than
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         in the pediatric population, more data are needed. An international clinical trial seeking to compare cisplatin- with carboplatin-containing regimens in children and adults is ongoing. Therefore, we reserve carboplatin as a substitute for cisplatin if there are contraindications to the use of cisplatin (eg, renal failure).
        </p>
        <p class="headingAnchor" id="H42">
         <span class="h2">
          Pregnant women
         </span>
         <span class="headingEndMark">
          —
         </span>
         OGCTs often occur in women of reproductive age; therefore, these tumors are one of the more common ovarian malignancies diagnosed in pregnancy [
         <a href="#rid73">
          73
         </a>
         ]. Chemotherapy treatment of OGCTs in pregnant women is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3198.html" rel="external">
          "Chemotherapy of ovarian cancer in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2116563292">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119533.html" rel="external">
          "Society guideline links: Ovarian, fallopian tube, and peritoneal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H43">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant ovarian germ cell tumors (OGCTs) include dysgerminomas (analogous to the male testicular seminoma) and nondysgerminomatous tumors. Nondysgerminomatous tumors include immature teratomas, embryonal cell carcinoma, yolk sac tumors, primary ovarian (nongestational) choriocarcinomas, polyembryoma, and mixed germ cell tumors. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The treatment principles for all types of malignant OGCTs are generally similar and include surgery for diagnosis and staging, cytoreductive surgery if advanced disease is present, and adjuvant chemotherapy in most cases  (
         <a class="graphic graphic_table graphicRef55704" href="/z/d/graphic/55704.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="local">
          'Overview'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         OGCTs occur predominantly in children and young women. For these patients, unilateral salpingo-oophorectomy with preservation of the uterus and the contralateral ovary may be performed if these organs appear normal. Standard surgical staging with total extrafascial hysterectomy and bilateral salpingo-oophorectomy is generally performed on women who have completed childbearing. (See
         <a class="local">
          'Children and adolescents'
         </a>
         above and
         <a class="local">
          'Fertility-sparing surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most adult women with a newly diagnosed OGCT, we recommend adjuvant chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Our regimen of choice is
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (BEP). Women with stage IA or IB dysgerminoma or stage IA, grade 1 immature teratomas have an excellent prognosis following surgical treatment alone, and therefore, we recommend against administering adjuvant chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Adjuvant treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All women should be followed by history and physical exam after the completion of treatment for OGCTs. Serum tumor markers should be followed serially as well. In keeping with the guidelines from the Society of Gynecologic Oncologists, we only perform radiographic surveillance within the first two years if tumor markers were not elevated initially. Given the risk for late relapse, dysgerminomas require annual follow-up for at least 10 years. (See
         <a class="local">
          'Post-treatment surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For women who relapse and did not receive chemotherapy previously (ie, in the adjuvant setting), we recommend platinum-based chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). As in the adjuvant setting, our regimen of choice is BEP. (See
         <a class="local">
          'Relapsed disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The approach to treatment for women with relapsed disease despite prior treatment with chemotherapy is extrapolated from the approach to men with relapsed or refractory testicular germ cell tumors. (See
         <a class="medical medical_review" href="/z/d/html/2999.html" rel="external">
          "Diagnosis and treatment of relapsed and refractory testicular germ cell tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For pediatric and adolescent girls (see
         <a class="local">
          'Children and adolescents'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We suggest postoperative surveillance for those with International Federation of Gynecology and Obstetrics (FIGO) stage IA and IB OGCTs (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         With the exception of patients with immature teratomas regardless of grade, we suggest adjuvant chemotherapy for those with more advanced disease (stage IC to IV) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For those with immature teratomas regardless of grade, we suggest observation rather than adjuvant chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As in adult women, our regimen of choice is BEP. However, carboplatin-based treatment appears to be a reasonable and less toxic regimen for use in this population, especially if there is a contraindication to
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2183606093">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate would like to recognize Eva Chalas, MD, FACOG, FACS, Fidel A Valea, MD, and William Mann, Jr, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Blaustein's Pathology of the Female Genital Tract, 4th ed, Blaustein A, Kurman RJ (Eds), Springer-Verlag, 1987.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shim SH, Kim DY, Lee SW, et al. Laparoscopic management of early-stage malignant nonepithelial ovarian tumors: surgical and survival outcomes. Int J Gynecol Cancer 2013; 23:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar S, Shah JP, Bryant CS, et al. The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol 2008; 110:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasioudis D, Ko EM, Haggerty AF, et al. Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy. Gynecol Oncol 2020; 157:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slayton RE, Park RC, Silverberg SG, et al. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer 1985; 56:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams SD, Blessing JA, Moore DH, et al. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med 1989; 111:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bafna UD, Umadevi K, Kumaran C, et al. Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors? Int J Gynecol Cancer 2001; 11:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenson DM, Morris M, Cangir A, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990; 8:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Papadopoulou M, Andreopoulou E, et al. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Gynecol Oncol 1998; 70:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000; 18:3809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams SD. Ovarian germ cell tumors: an update. Semin Oncol 1998; 25:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segelov E, Campbell J, Ng M, et al. Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience. J Clin Oncol 1994; 12:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rescorla F, Billmire D, Vinocur C, et al. The effect of neoadjuvant chemotherapy and surgery in children with malignant germ cell tumors of the genital region: a pediatric intergroup trial. J Pediatr Surg 2003; 38:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talukdar S, Kumar S, Bhatla N, et al. Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary. Gynecol Oncol 2014; 132:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol 1994; 12:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Culine S, Lhomme C, Kattan J, et al. Cisplatin-based chemotherapy in the management of germ cell tumors of the ovary: The Institut Gustave Roussy Experience. Gynecol Oncol 1997; 64:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenson DM, Kavanagh JJ, Copeland LJ, et al. Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatin. Cancer 1986; 57:1731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson RW, Sikic BI, Turbow MM, Ballon SC. Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary. J Clin Oncol 1983; 1:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor MH, Depetrillo AD, Turner AR. Vinblastine, bleomycin, and cisplatin in malignant germ cell tumors of the ovary. Cancer 1985; 56:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayordomo JI, Paz-Ares L, Rivera F, et al. Ovarian and extragonadal malignant germ-cell tumors in females: a single-institution experience with 43 patients. Ann Oncol 1994; 5:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tewari K, Cappuccini F, Disaia PJ, et al. Malignant germ cell tumors of the ovary. Obstet Gynecol 2000; 95:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith JP, Rutledge F. Advances in chemotherapy for gynecologic cancer. Cancer 1975; 36:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murugaesu N, Schmid P, Dancey G, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 2006; 24:4862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers PC, Olson TA, Cullen JW, et al. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol 2004; 22:3563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Culine S, Lhomme C, Kattan J, et al. Cisplatin-based chemotherapy in dysgerminoma of the ovary: thirteen-year experience at the Institut Gustave Roussy. Gynecol Oncol 1995; 58:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brewer M, Gershenson DM, Herzog CE, et al. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999; 17:2670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah R, Xia C, Krailo M, et al. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecol Oncol 2018; 150:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams SD, Kauderer J, Burnett AF, et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol 2004; 95:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park JY, Kim DY, Suh DS, et al. Outcomes of Surgery Alone and Surveillance Strategy in Young Women With Stage I Malignant Ovarian Germ Cell Tumors. Int J Gynecol Cancer 2016; 26:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patterson DM, Murugaesu N, Holden L, et al. A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer 2008; 18:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Billmire DF, Cullen JW, Rescorla FJ, et al. Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology Group. J Clin Oncol 2014; 32:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mangili G, Scarfone G, Gadducci A, et al. Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). Gynecol Oncol 2010; 119:48.
          </a>
         </li>
         <li class="breakAll">
          Active surveillance, bleomycin, etoposide, carboplatin or cisplatin in treating pediatric and adult patients with germ cell tumors. https://clinicaltrials.gov/ct2/show/NCT03067181 (Accessed on April 01, 2022).
         </li>
         <li class="breakAll">
          Stambaugh MD. Ovary. In: Principles and Practice of Radiation Oncology, 4th ed, Perez CA, Brady LW, Halperin CA, Schmidt-Ullrich RK (Eds), Lippincott, Williams and Wilkins, Philadelphia 1997. p.1948.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenson DM, Del Junco G, Copeland LJ, Rutledge FN. Mixed germ cell tumors of the ovary. Obstet Gynecol 1984; 64:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenson DM, Del Junco G, Herson J, Rutledge FN. Endodermal sinus tumor of the ovary: the M. D. Anderson experience. Obstet Gynecol 1983; 61:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krepart G, Smith JP, Rutledge F, Delclos L. The treatment for dysgerminoma of the ovary. Cancer 1978; 41:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Palo G, Lattuada A, Kenda R, et al. Germ cell tumors of the ovary: the experience of the National Cancer Institute of Milan. I. Dysgerminoma. Int J Radiat Oncol Biol Phys 1987; 13:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teinturier C, Gelez J, Flamant F, et al. Pure dysgerminoma of the ovary in childhood: treatment results and sequelae. Med Pediatr Oncol 1994; 23:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hale GA, Marina NM, Jones-Wallace D, et al. Late effects of treatment for germ cell tumors during childhood and adolescence. J Pediatr Hematol Oncol 1999; 21:115.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2023. Available at: https://www.nccn.org/professionals/physician_gls/ https://www.nccn.org/professionals/physician_gls/ (Accessed on November 29, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai CH, Chang TC, Hsueh S, et al. Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 2005; 96:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med 2005; 50:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maltaris T, Boehm D, Dittrich R, et al. Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol 2006; 103:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenson DM, Miller AM, Champion VL, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:2792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 2003; 101:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer 2000; 89:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanetta G, Bonazzi C, Cantù M, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001; 19:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peccatori F, Bonazzi C, Chiari S, et al. Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients. Obstet Gynecol 1995; 86:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Billmire D, Vinocur C, Rescorla F, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 2004; 39:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanagnolo V, Sartori E, Galleri G, et al. Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004; 25:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon A, Lipton D, Woodruff JD. Dysgerminoma: a review of 158 cases from the Emil Novak Ovarian Tumor Registry. Obstet Gynecol 1981; 58:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopes LF, Macedo CR, Pontes EM, et al. Cisplatin and etoposide in childhood germ cell tumor: brazilian pediatric oncology society protocol GCT-91. J Clin Oncol 2009; 27:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell PL, Al-Nasiri N, A'Hern R, et al. Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases. Cancer 1999; 85:2232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayordomo JI, Paz-Ares L, Diaz-Puente MT, et al. Prognostic factors for women with ovarian germ cell tumors. J Clin Oncol 1994; 12:1737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrne J, Fears TR, Gail MH, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992; 166:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006; 98:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrison A, Nasioudis D. Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature. Gynecol Oncol 2020; 158:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000; 92:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matei D, Miller AM, Monahan P, et al. Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27:4142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdul Razak AR, Li L, Bryant A, Diaz-Padilla I. Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease. Cochrane Database Syst Rev 2011; :CD007584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandanas RA, Saez RA, Epstein RB, et al. Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors. Bone Marrow Transplant 1998; 21:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theodore C, Chevreau C, Yataqhene Y, et al. A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol 2008; 19:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams SD, Blessing JA, DiSaia PJ, et al. Second-look laparotomy in ovarian germ cell tumors: the gynecologic oncology group experience. Gynecol Oncol 1994; 52:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munkarah A, Gershenson DM, Levenback C, et al. Salvage surgery for chemorefractory ovarian germ cell tumors. Gynecol Oncol 1994; 55:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Yang W, Wu X. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients. Gynecol Oncol 2007; 105:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez-Galindo C, Krailo M, Frazier L, et al. Children's Oncology Group's 2013 blueprint for research: rare tumors. Pediatr Blood Cancer 2013; 60:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasioudis D, Mastroyannis SA, Latif NA, Ko EM. Trends in the surgical management of malignant ovarian germcell tumors. Gynecol Oncol 2020; 157:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pashankar F, Hale JP, Dang H, et al. Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. Cancer 2016; 122:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stern JW, Bunin N. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med Pediatr Oncol 2002; 39:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Novak ER, Lambrou CD, Woodruff JD. Ovarian tumors in pregnancy. An ovarian tumor registry review. Obstet Gynecol 1975; 46:401.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3197 Version 40.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Blaustein's Pathology of the Female Genital Tract, 4th ed, Blaustein A, Kurman RJ (Eds), Springer-Verlag, 1987.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23318909" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Laparoscopic management of early-stage malignant nonepithelial ovarian tumors: surgical and survival outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18571705" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32359845" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2988740" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2472080" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11520369" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1690272" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9698477" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11078494" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9633853" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Ovarian germ cell tumors: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8113845" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12778391" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The effect of neoadjuvant chemotherapy and surgery in children with malignant germ cell tumors of the genital region: a pediatric intergroup trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24145115" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7512129" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8995567" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cisplatin-based chemotherapy in the management of germ cell tumors of the ovary: The Institut Gustave Roussy Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2420435" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6199468" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2411377" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Vinblastine, bleomycin, and cisplatin in malignant germ cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7514435" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Ovarian and extragonadal malignant germ-cell tumors in females: a single-institution experience with 43 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10636515" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Malignant germ cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1157027" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Advances in chemotherapy for gynecologic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17050871" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337806" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7672699" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cisplatin-based chemotherapy in dysgerminoma of the ovary: thirteen-year experience at the Institut Gustave Roussy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10561340" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Outcome and reproductive function after chemotherapy for ovarian dysgerminoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29884437" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15581952" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27101582" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Outcomes of Surgery Alone and Surveillance Strategy in Young Women With Stage I Malignant Ovarian Germ Cell Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17466047" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24395845" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20599258" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20599258" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20599258" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6204258" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Mixed germ cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6185892" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Endodermal sinus tumor of the ovary: the M. D. Anderson experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/638985" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The treatment for dysgerminoma of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3583856" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Germ cell tumors of the ovary: the experience of the National Cancer Institute of Milan. I. Dysgerminoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8177140" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pure dysgerminoma of the ovary in childhood: treatment results and sequelae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10206457" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Late effects of treatment for germ cell tumors during childhood and adolescence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10206457" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Late effects of treatment for germ cell tumors during childhood and adolescence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15721426" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Outcome and prognostic factors in ovarian germ cell malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16050566" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Update on the management of ovarian germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16996582" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Reproduction beyond cancer: a message of hope for young women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17602084" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12576247" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10918171" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11181664" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Survival and reproductive function after treatment of malignant germ cell ovarian tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7651644" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15017564" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15171308" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Clinical review of 55 cases of malignant ovarian germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7279343" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Dysgerminoma: a review of 158 cases from the Emil Novak Ovarian Tumor Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19164215" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Cisplatin and etoposide in childhood germ cell tumor: brazilian pediatric oncology society protocol GCT-91.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10326703" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8040686" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Prognostic factors for women with ovarian germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21752752" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1550144" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Early menopause in long-term survivors of cancer during adolescence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16818852" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32513565" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10904090" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Treatment-associated leukemia following testicular cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1713639" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19636015" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21412906" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9543060" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18385203" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8157184" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Second-look laparotomy in ovarian germ cell tumors: the gynecologic oncology group experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7959287" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Salvage surgery for chemorefractory ovarian germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17459461" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23255219" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Children's Oncology Group's 2013 blueprint for research: rare tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32008791" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Trends in the surgical management of malignant ovarian germcell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26485622" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12210444" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1165873" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Ovarian tumors in pregnancy. An ovarian tumor registry review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
